Lifecare ASA

Regulatory Filings • Aug 27, 2025

Reconfirmed positive results in veterinary study support path toward market entry

Reconfirmed positive results in veterinary study support path toward market entry

Bergen, Norway, 27 August 2025 -- Lifecare ASA (LIFE), a MedTech company

developing next generation Continuous Glucose Monitoring (CGM) technology for

diabetes managment, announces that the second veterinary subject in its

ongoing longevity study (LFC-SEN-002) has confirmed the positive findings

observed in the first subject.

Summary:

* Data from second subject reconfirms safety, biocompatibility, and

suitability for long-term use in ongoing veterinary study LFC-SEN-002.

* Study results build on earlier human data confirming accurate glucose

measurement (LFC-SEN-001).

* Longevity study LFC-SEN-002 is still ongoing and planned to continue under

extended approval.

* Recent media events force the company to safeguarding shareholder trust

through a PFU filing.

Reference is made to Lifecares press release 8 November 2024. The purpose of

LFC-SEN-002 is to evaluate sensor efficacy for glucose measurement in dogs and

to document longevity, tolerability, and biocompatibility. The previous human

study (LFC-SEN-001) demonstrated glucose measurement performance on par with

commercially available CGM systems.

The ongoing veterinary longevity study (LFC-SEN-002) focuses on product

development aspects, including electronic performance, signal range, radio and

Bluetooth connectivity, and power consumption under real-life conditions.

Following 90 days of implantation, histopathological analyses performed by the

Norwegian University of Life Sciences (NMBU) confirmed that the device was

well tolerated, showing only mild localized tissue reactions consistent with a

normal foreign-body response. Importantly, no adverse events were observed,

reinforcing evidence that Lifecare's CGM device is safe and biocompatible for

long-term implantation.

The current approval for veterinary studies expires at the end of August.

Lifecare has already resubmitted the protocol to secure a continued approval,

as LFC-SEN-002 will continue until the company formally defines study end.

Additional subjects are planned for enrolment, expanding the scope beyond

longevity and tolerability to further validate glucose measurement performance

in both healthy and diabetic animals.

Safeguarding shareholder trust throug transparency

In addition to disclosure of positive and re-confirmative study data, this

announcement addresses recent media coverage that was based on information

Lifecare had refuted with documentation, prior to publication. This media

coverage was speculative, inaccurate, and strongly misleading, undermining

confidence in the company's technology and communication. This false,

misleading and inaccurate coverage seems to have directly affected the

company's market valuation.

As a publicly listed company, Lifecare has a duty to protect its shareholders

by ensuring that accurate and reliable information reaches the market. To

safeguard this principle, the company will file a formal complaint with the

Norwegian Press Complaints Commission (Pressens Faglige Utvalg, PFU). In

Lifecare's view, the coverage in question failed to meet basic press ethics

standards of accuracy and fairness.

Lifecare regards this as a matter of principle---both to protect shareholder

value and to uphold trust in transparent market communication.

The company reiterates its strong belief in the future of its technology and

its ability to deliver meaningful innovation for people living with diabetes.

Entering a defining phase, Lifecare moves forward with confidence ---

supported by proven results, a solid strategy, and a committed team.

About us

Lifecare ASA is a medical sensor company developing technology for sensing and

monitoring of various body analytes. Lifecare's focus is to bring the next

generation of Continuous Glucose Monitoring ("CGM") systems to market.

Lifecare enables osmotic pressure as sensing principle. Lifecare's sensor

technology is suitable for identifying and monitoring the occurrence of a wide

range of analytes and molecules in the human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42